AstraZeneca Links Up Durvalumab With Lion
This article was originally published in Scrip
AstraZeneca's MedImmune inked its latest immuno-oncology collaboration with Lion Biotechnologies Inc. for its PD-L1 inhibitor durvalumab.
Lion will conduct two Phase IIa clinical trials of durvalumab in combination with its tumor-infiltrating lymphocytes (TIL) in patients with metastatic melanoma and neck cancer in order to establish safety and efficacy of the combined drugs.
Further preclinical research, funded by MedImmune and conducted by Lion, will use the TIL and MedImmune's checkpoint inhibitors to find other therapeutic combinations.
Financial terms of the agreement have not been disclosed.
AstraZeneca, as well as other big pharmas, have been inking partnership after partnership for their respective PD-1/PD-L1 inhibitors. Clinicians believe that combination therapies are going to be the future of cancer treatments.